Oxfendazole curbs osteosarcoma-driven bone destruction in preclinical models
Osteosarcoma does not only threaten patients through uncontrolled tumor growth. Its most damaging local effect may be the bone destruction it leaves behind, where tumor cells and osteoclasts reinforce one another inside an osteolytic microenvironment. In this preclinical study, oxfendazole emerged as a repurposed drug candidate capable of interrupting that destructive loop, even though it did not significantly shrink the primary tumor itself.
The work used single-cell RNA sequencing to search for regulators of osteoclast differentiation in the setting of osteosarcoma. That approach matters because the tumor microenvironment is not a uniform mass; it is a shifting cellular network in which immune cells, stromal cells, and bone-resorbing osteoclasts can be driven into pro-destruction states by local signaling. By focusing at single-cell resolution, the investigators were able to identify a targetable biologic pattern rather than relying on bulk tissue averages that can blur rare but clinically important populations.
A drug-screening pipeline built around the Beyondcell platform then pointed to oxfendazole as a candidate agent. ANXA2 emerged as a key associated target. The mechanistic logic is straightforward: if a compound can blunt the molecular program that supports osteoclast differentiation, it may reduce bone resorption even when the tumor remains present. In osteosarcoma, that separation is clinically important because the immediate threat is often not only metastatic spread but also pain, fracture risk, and local skeletal collapse.
Bone-resorption suppression outpaced tumor control
In vitro osteoclastogenesis assays showed that oxfendazole interfered with osteoclast formation. In an in vivo tibial orthotopic osteosarcoma model, oral administration via gavage also suppressed osteoclast formation and osteolytic activity. Micro-CT and histopathologic analyses supported those findings.
Oxfendazole alone did not significantly inhibit osteosarcoma growth. The drug’s benefit came from reducing osteoclast-mediated osteolysis, not from direct tumor shrinkage. For bedside interpretation, that distinction is critical: a therapy can still be biologically valuable if it stabilizes bone, limits pathological fracture, and softens the local destructive environment that supports tumor progression and metastatic dissemination. In that sense, the study isolates a bone-directed effect rather than a broad antitumor effect.
The preclinical data also align with a long-standing therapeutic gap in osteosarcoma care. Conventional osteoclast-targeting agents have not been sufficient to suppress the aggressive bone resorption driven by osteosarcoma. The present findings suggest that the problem may not be a lack of bone-active therapy in general, but a need for agents that hit the specific signaling machinery operating inside the tumor-bone interface.
ANXA2 downregulation links oxfendazole to impaired osteoclast differentiation
qRT-PCR and immunohistochemistry confirmed that oxfendazole downregulated ANXA2 expression both in vitro and in vivo. That molecular change offers a plausible explanation for the drop in osteoclast differentiation, since the osteoclast lineage depends on tightly regulated transcriptional and signaling programs to mature and resorb mineralized matrix. When those programs are suppressed, bone erosion should slow, and the osteolytic surface available for tumor exploitation shrinks with it.
Molecular dynamics simulations, paired with in vitro validation, suggested a further upstream mechanism involving ZNF530. Oxfendazole may interact with this transcription factor, leading to reduced ANXA2 transcription. The study therefore sketches a chain of events from computational drug selection to transcriptional suppression and then to impaired osteoclastogenesis. Although these findings remain preclinical, they give the compound a coherent mechanistic identity rather than presenting it as a nonspecific inhibitor.
Why this matters for osteosarcoma care
The clinical burden of osteosarcoma-associated osteolysis is not abstract. Pathological fractures, severe pain, and progressive bone loss directly shape quality of life and can complicate local disease control. A drug that reduces osteoclast activity without requiring direct tumor cytoreduction could fill a different therapeutic niche from standard antineoplastic agents. It may become relevant as a supportive or adjunctive strategy if later studies confirm safety, exposure, and efficacy in patients.
Still, the evidence stops at the preclinical boundary. The study was conducted through single-cell transcriptomic analysis, computational screening, cell-based osteoclast assays, and an orthotopic mouse model. No human treatment data are included. The work also does not establish whether oral oxfendazole can reach the relevant bone microenvironment at sufficient concentrations in people, whether its pharmacology would mirror the murine setting, or whether ANXA2 suppression would translate into durable clinical benefit.
Repurposing a parasitic agent for bone-targeted oncology
The most intriguing aspect of the study is repurposing. Oxfendazole is already known as an anti-parasitic drug, yet here it was identified for a completely different biologic task: restraining osteoclast-driven skeletal destruction. Repurposing can shorten the path from discovery to application when a compound already has known chemistry and prior exposure history, but that shortcut should not be overstated. A drug with familiar labeling still requires careful dose, toxicity, and pharmacokinetic evaluation in a new disease context.
The data also suggest that osteosarcoma treatment may benefit from a more layered strategy. Tumor cells and bone-resorbing cells communicate bidirectionally, and the microenvironment itself can amplify both invasion and dissemination. Interrupting osteoclast differentiation may not eradicate the malignancy, but it could weaken the structural and biological support system that allows the disease to inflict such disproportionate damage on the skeleton.
The study ends where most useful preclinical work should: with a specific mechanism, a defined candidate compound, and a clear set of unanswered translational questions. Whether oxfendazole can become a practical therapy for patients with osteosarcoma-associated osteolysis will depend on future studies that move beyond mouse bone and into human pharmacology, safety, and clinical effect.
- • PLOS Computational Biology DOI 10.1371/journal.pcbi.1014828: https://doi.org/10.1371/journal.pcbi.1014828